Last updated on April 2019

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time) | Hemorrhage | Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation | Acute Bleeding on Long-Term Anticoagulation Therapy
  • Age: Between 18 - 125 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Chronic anticoagulation with warfarin and initial INR 2
  • Emergent bleeding (i.e. intracranial hemorrhage, gastrointestinal hemorrhage, urgent invasive procedures, etc.) or urgent surgery requiring reversal of INR to 1.5

Exclusion Criteria:

  • Younger than 18 years of age
  • History of heparin-induced thrombocytopenia (HIT)
  • Patients without initial or post-administration INR readings
  • Patients with an initial INR <2
  • Pregnant patients
  • Prisoners

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.